Merck的新HIV药物在晚期试验中显示出有希望的成果, 有可能提供更简单的治疗方案。 Merck's new HIV drug shows promising results in late-stage trials, potentially offering a simpler treatment regimen.

Merck新的两药艾滋病毒治疗 -- -- doravirine/islatravir -- -- 显示在两次后期试验中取得了积极成果,至少证明与目前治疗一样有效,没有重大安全问题。 Merck's new two-drug HIV treatment, doravirine/islatravir, shows positive results in two late-stage trials, proving at least as effective as current treatments without significant safety issues. 该药物针对的是艾滋病毒-1感染的成人,可以提供更简单的每日一次治疗办法。 The drug is intended for HIV-1 infected adults and could offer a simpler once-daily regimen. Merck计划提交这些调查结果供监管批准,并在今后的医疗会议上提交详细结果。 Merck plans to submit these findings for regulatory approval and present detailed results at future medical conferences.